INCIDENCE AND MORTALITY FROM BREAST CANCER IN THE MALE AND FEMALE POPULATION OF CENTRAL SERBIA IN THE PERIOD 2009-2020
Abstract
Introduction/Aim: In 2020, globally, breast cancer was the leading cause of morbidity when both sexes are considered together, followed by prostate cancer and lung cancer. However, breast cancer is very rare in men. In this descriptive study, incidence and mortality from breast cancer was analyzed in the population of men and women in Central Serbia for the period from 2009 to 2020.
Methods: Data on patients and deaths from breast cancer, as well as the number of inhabitants, by gender and age, were taken from published and unpublished material of the Institute for Public Health of Serbia "Dr. Milan Jovanović Batut". General, specific and standardized incidence and mortality rates were used in the analysis. Joinpoint regression analysis was used to analyze trends in morbidity and mortality.
Results: In the period 2009-2020, the average standardized incidence rate (per 100,000) of breast cancer for men was 1.3, and for women 65.3, and the mortality rate (per 100,000) for women was 19.8, and for men 0.4. During the observed period, the standardized incidence rate for men increased by 1.9% per year and the mortality rate by 2.4%, but without significance. In women, the standardized incidence rate increased significantly by 3.5% per year in the period 2013-2020, and the standardized mortality rate significantly decreased by -0.5% per year in the period 2009-2020. In both sexes, mortality and incidence rates increased with age, except that in women the incidence rate for the age of 70 and over was lower compared to the incidence rate for the age of 60-69.
Conclusion: It is necessary to further improve the implementation of organized screening for breast cancer in the territory of Central Serbia, as well as to work on the reduction/elimination of risk factors and raise the awareness of men about the possibility that they can be affected by breast cancer.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3): 209-49. doi: 10.3322/caac.21660.
2. Zehr KR. Diagnosis and Treatment of Breast Cancer in Men. Radiol Technol 2019;91(1):51M-61M.
3. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022;66:15-23. doi: 10.1016/j.breast.2022.08.010.
4. Fakhri N, Chad MA, Lahkim M, Houari A, Dehbi H, Belmouden A, El Kadmiri N. Risk factors for breast cancer in women: an update review. Med Oncol 2022;39(12):197. doi: 10.1007/s12032-022-01804-x. PMID: 36071255.
5. Šipetic-GrujičićS,MurtezaniZ,RatkovI,GrgurevicA,MarinkovicJ,BjekicM,etal. Comparison of male and female breast cancer incidence and mortality trends in Central Serbia. Asian Pac J Cancer Prev APJCP 2013;14(10):5681–5.
6. Segi’s world standard population (1960) [Internet]. [cited 2023 Feb 23]. Available from: https://www.e-crt.org/upload/media/crt-2017-464-suppl1.pdf
7. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19(3):335–51.
8. Brinton LA, Gaudet MM, Gierach GL. Breast cancer. In: M Thun, MS Linet, JR Cerhan, CA Haiman, D Schottenfeld, eds. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press; 2018: 861- 88.
9. Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387-91.
10. Suggested Citation Centers for Disease Control and Prevention. Male Breast Cancer Incidence and Mortality, United States—2013–2017. USCS Data Brief, no. 19. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020
11. Abdelwahab Yousef AJ. Male Breast Cancer: Epidemiology and Risk Factors. Seminars in Oncology 2017; 44(4):267-72. https://www.sciencedirect.com/journal/seminars-in-oncology/vol/44/issue/4>
12. Ferzoco RM, Ruddy KJ. The Epidemiology of Male Breast Cancer. Curr Oncol Rep 2016;18(1):1. doi: 10.1007/s11912-015-0487-4. PMID: 26694922.
13. Co M, Lee A, Kwong A. “Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer. Cancer Medicine 2020;9(10):3305–9.
14. Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Male breast cancer. Crit Rev Oncol Hematol 2010;73(2):141–55.
15. Pizzato M, Carioli G, Bertuccio P, Malvezzi M, Levi F, Boffetta P, et al. Trends in male breast cancer mortality: a global overview. Eur J Cancer Prev 2021;30(6):472-9. doi: 10.1097/CEJ.0000000000000651. PMID: 33470692.
16. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99(15):1152–61.
17.Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer 2011;117(10):2209–18.
18. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356(16):1670–4.
19. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control CCC. 2010;21(1):83–90.
20. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a populationbased study. Lancet Glob Health 2020;8(8):e1027–37.
21. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin 2019;69(6):438–51.
22. Anderson WF, Rosenberg PS, Petito L, Katki HA, Ejlertsen B, Ewertz M, et al. Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer 2013;133(9):2201–6.
23. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 2014;36(1):114–36.
23. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34(2):405–12.
24. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population based registries in 71 countries. Lancet Lond Engl 2018;391(10125):1023–75.
25. Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N’da G, et al. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. Int J Cancer. 2020 Mar 1;146(5):1208–18.
26. Verhoeven D, Kaufman C, Mansel R, Siesling S, Verhoeven D, Kaufman C, et al. (editors). Breast cancer: Global quality care. Oxford, New York: Oxford University Press; 2019.
27. [ARCHIVED CONTENT] Cancer Registrations - ONS [Internet]. [cited 2023 Feb 23]. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20160105163713/http://www.ons.g ov.uk/ons/taxonomy/index.html?nscl=Cancer+Registrations